Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

This is the study of 64Cu-FAPI-XT117, which is an prospective, single-arm phase I clinical study.

Inclusion Criteria:

• 1. signed the informed consent
• 2. ≥18 years old
• 3. confirmed as malignant solid tumor by histopathology or clinical judgment
• 4. Patients will undergo 18F-FDG PET/CT examination

Exclusion Criteria:

• 1. Known allergy to components of the investigational drug or its analogues
• 2. suspected to have a certain disease or condition that is not suitable for the study drug
• 3. Known pregnant or lactating women